Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canrenoic acid is a synthetic steroidal antimineralocorticoid and a monocarboxylic acid that acts as an aldosterone antagonist. It is not marketed directly but is used clinically in the form of its potassium salt (potassium canrenoate). Canrenoic acid functions as a prodrug and is metabolized to the active compound canrenone in the body. Its primary mechanism of action involves antagonism of the mineralocorticoid receptor (aldosterone receptor), leading to diuretic effects useful in conditions such as primary hyperaldosteronism and disorders related to excess aldosterone. Like spironolactone, it belongs to the spirolactone group of drugs[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on canrenoic acid.